Zusammenfassung
Kutane Lymphome sind seltene Hauterkrankungen. Sie sind von sekundären Hautinfiltraten bei primär nodalen Lymphomen abzugrenzen. Die primären kutanen Lymphome können in B- und T-Zell-Lymphome unterteilt werden und weisen meist eine insgesamt günstige Prognose mit chronischem Verlauf auf. Die Therapie ist stadienabhängig. Da eine Heilung nicht möglich ist, gilt es, den Krankheitsverlauf unter Kontrolle zu halten und die Symptome zu lindern. In letzter Zeit wurden viele neue Medikamente mit Erfolg eingesetzt.
Abstract
Cutaneous lymphomas are uncommon. They must be distinguished from secondary skin manifestations of primary nodal lymphomas. Primary cutaneous lymphomas are divided into B-cell- and T-cell cutaneous lymphoma and commonly have good prognosis. Therapy is based on the stage of the disease. Since cure is not possible, the aim of treatment is to control the disease and reduce symptoms. A variety of new and promising therapeutic modalities have been introduced in recent years.
This is a preview of subscription content, log in via an institution to check access.
Literatur
Bekkenk MW, Geelen FA, van Voorst Vader PC et al. (2000) Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 95:3653–3661
Burg G, Dummer R, Dommann S et al. (1995) Pathology of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 9:961–997
Dummer R, Kamarashev J, Kempf W et al. (2002) Junctional CD8+ cutaneous lymphomas with nonaggressive clinical behavior: a CD8+ variant of mycosis fungoides? Arch Dermatol 138:199–203
Grange F, Bekkenk MW, Wechsler J et al. (2001) Prognostic factors in primary cutaneous large B-cell lymphomas: a European multicenter study. J Clin Oncol 19:3602–3610
Kaye FJ, Bunn PJ, Steinberg SM et al. (1989) A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 321:1784–1790
Kempf W, Dummer R, Burg G (1999) Approach to lymphoproliferative infiltrates of the skin. The difficult lesions. Am J Clin Pathol 111 [Suppl 1]:S84–93
Kerl H, Cerroni L, Fink-Puches R, Wolf IH (2004) Primäre kutane B-Zell-Lymphome. JDDG 7:605–621
Petrella T, Dalac S, Maynadie M et al. (1999) CD4+ CD56+ cutaneous neoplasms: a distinct hematological entity? Groupe Francais d’Etude des Lymphomes Cutanes (GFELC). Am J Surg Pathol 23:137–146
Stadler R, Otte HG, Luger T et al. (1998) Prospective randomized multicenter clinical trial on the use of interferon-2a plus acitretin versus interferon-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood 92:3578–3581
Vonderheid EC, Bernengo MG, Burg G et al. (2002) Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol 46:95–106
Willemze R, Kerl H, Sterry W et al. (1997) EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 90:354–371
Wollina U, Graefe T, Kaatz M (2001) Pegylated doxorubicin for primary cutaneous T cell lymphoma: a report on ten patients with follow-up. Ann N Y Acad Sci 941:214–216
Interessenkonflikt:
Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Beyeler, M., Burg, G. & Dummer, R. Kutane Lymphome. Hautarzt 55, 1005–1017 (2004). https://doi.org/10.1007/s00105-004-0816-2
Issue Date:
DOI: https://doi.org/10.1007/s00105-004-0816-2